This study is in progress, not accepting new patients

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

a study on Solid Tumor Lymphoma Stomach Cancer Colorectal Cancer Head and Neck Cancer Squamous Cell Carcinoma Breast Cancer HER2 Hepatocellular Cancer Hepatocellular Carcinoma Liver Cancer Lung Cancer Kidney Cancer Renal Cell Carcinoma Pancreatic Cancer Skin Cancer/Melanoma Non-Small Cell Lung Cancer Transitional Cell Carcinoma Cervical Cancer Microsatellite Instability Merkel Cell Carcinoma Immunotherapy Carcinoma Pancreatic Neoplasms

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Diego, California and other locations
Dates
study started
estimated completion

Description

Summary

Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study.

The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.

Details

This is a multicenter, non-interventional, observation study designed to provide long-term safety and efficacy data on subjects who have participated in a prior Fate Therapeutics interventional study of FT500 cellular immunotherapy. Subjects will be contacted every six months (± one month), beginning six months after subject completion or withdrawal from the FT500-101 study.

Keywords

Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma, Carcinoma, Small Cell Lung Carcinoma, Pancreatic Neoplasms, Allogeneic natural killer (NK) cell

Eligibility

You can join if…

Open to people ages 18 years and up

  • Subjects who received an allogeneic, iPSC-derived NK cell in a Fate Therapeutics interventional study
  • Subjects who have provided Informed consent prior to their study participation

You CAN'T join if...

- Not Applicable

Locations

  • UCSD Moores Cancer Center
    San Diego California 92093 United States
  • MD Anderson Cancer Center
    Houston Texas 77030 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Fate Therapeutics
ID
NCT04106167
Study Type
Observational
Participants
About 20 people participating
Last Updated